Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyOscar Health pathogen panel coverage & prior auth …
    Ask Trek AI about this page
    CurrentOscar HealthPolicy N/A

    Pathogen Panel Testing

    Customize your policy alerts

    Sign up for all Oscar Health policy alerts

    Know when Oscar Health releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Rules for outpatient pathogen panel diagnostic testing (multiplex PCR and antigen panels) including indications, limitations, and which panels meet or do not meet coverage criteria for Oscar Health members.

    Policy Summary
    PayerOscar Health
    PolicyPathogen Panel Testing
    Policy CodePolicy N/A
    Change TypeRoutine review — no material changes
    Effective DateOct 1, 2026
    Last ReviewJun 16, 2026
    Next Review DateJun 16, 2026
    Key ActionObtain prior authorization when broad multiplex panels are ordered for low‑risk outpatients or when member benefits require authorization; document clinical justification.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    up to 11GI panels meeting criteria
    12+GI panels not meeting criteria
    up to 5Respiratory panels (typical)
    up to 25Respiratory panels — immunocompromised

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Not covered
    CSF / blood / urine / wound panels

    Coverage Criteria for Multiplex Pathogen Panels

    inv-01: Outpatient gastrointestinal and respiratory panel coverage

    Covered when the listed conditions are met in the outpatient setting:

    Gastrointestinal panel (multiplex PCR up to 11 targets): For individuals with persistent diarrhea or diarrhea with signs or risk factors for severe disease (eg, fever, bloody diarrhea, dysentery, dehydration, severe abdominal pain), multiplex PCR-based panel testing (up to 11 gastrointestinal pathogens) no more often than once every 7 days MEETS CRITERIA.up to 11 targets; frequency no more often than once every 7 days

    Outpatient setting only; see Note 1 for respiratory symptoms definition

    Respiratory panel (up to 5 targets): For individuals who are displaying signs and symptoms of a respiratory tract infection (see Note 1), panel testing of up to 5 respiratory pathogens (antigen panel testing or multiplex PCR-based panel testing) MEETS CRITERIA.up to 5 targets

    See Note 1 for respiratory signs and symptoms

    Respiratory panel - immunocompromised (up to 25 targets): For immunocompromised individuals who are displaying signs and symptoms of a respiratory tract infection (see Note 1), multiplex PCR-based panel testing of up to 25 respiratory pathogens MEETS CRITERIA.up to 25 targets

    Immunocompromised population only

    inv-02: Panels that do NOT meet criteria

    The following molecular or multiplex panel tests in the outpatient setting do NOT meet criteria:

    Gastrointestinal panels >=12 targets: Multiplex PCR-based panel testing of 12 or more gastrointestinal pathogens DOES NOT MEET CRITERIA.>=12 targets

    Lack of evidence for benefit in outpatient setting

    Large respiratory panels (>=6 targets outside specified): For all situations not described above, antigen panel testing or multiplex PCR-based panel testing of 6 or more respiratory pathogens DOES NOT MEET CRITERIA.>=6 targets unless immunocompromised allowance applies

    Exception: immunocompromised individuals may receive panels up to 25 targets

    CSF panels: Multiplex PCR-based panel testing of pathogens in cerebrospinal fluid (CSF) DOES NOT MEET CRITERIA.CSF panels

    inv-03: CNS panel medical necessity

    Molecular CSF testing (meningitis/encephalitis panel) is clinically appropriate when CSF findings and clinical presentation indicate a moderate-to-high pre-test probability.

    CNS molecular testing criteria: Order multiplex CSF PCR only when: (1) clinical presentation suggests meningitis or encephalitis AND (2) CSF screening studies (cell count, protein, glucose) are abnormal (elevated leukocyte count or protein) or there is heightened clinical suspicion (e.g., suspected HSV encephalitis).moderate-to-high pre-test probability

    Testing in absence of supportive CSF findings increases false positives and reduces predictive value; negative multiplex results do not exclude some encephalitides; consider adjunct serology or specific NAATs as needed

    inv-04: Respiratory panel coverage criteria

    Respiratory multiplex testing should be targeted to scenarios where results will change management.

    Acceptable uses of expanded respiratory panels: Use expanded multiplex respiratory NAATs when: (A) patient is immunocompromised or critically ill; OR (B) targeted testing (influenza/RSV/SARS-CoV-2) is negative but clinical suspicion remains high; OR (C) testing results will alter inpatient management (eg, cohorting, antibiotic stewardship).clinical impact on management

    In immunocompetent outpatients with mild/moderate illness prefer point-of-care influenza/RSV/SARS-CoV-2 testing due to greater demonstrated clinical impact

    inv-05: Sepsis panel coverage criteria

    Sepsis and bloodstream infection molecular testing is reasonable as an adjunct to blood culture when rapid identification will affect the choice or timing of therapy.

    Sepsis panel use cases: Use multiplex molecular assays for bloodstream infections when: (1) rapid identification is needed to guide antimicrobial therapy; AND (2) blood cultures are positive or antibiotics were administered prior to culture making culture less sensitive; OR (3) the assay will identify resistance genes that influence therapy.positive blood culture or pre-culture antibiotics; presence of clinical need for rapid ID

    These assays shorten time to organism/resistance identification and can promote judicious antibiotic use; use as adjunct to, not replacement for, culture when required

    inv-06: GI and UTI panel coverage criteria

    Gastrointestinal and UTI panels have higher analytic sensitivity but variable impact on clinical outcomes; use where etiologic diagnosis will influence treatment or public health actions.

    GI/UTI panel appropriate use: Consider multiplex GI panels for acute diarrheal disease when results will influence patient management, outbreak investigation, or when traditional methods are insufficient; consider molecular UTI testing when culture is negative but clinical suspicion persists or for complex/recurrent infections where resistance profiling is needed.clinical utility, outbreak investigation, or high-risk/complex patient

    Some studies show improved organism detection but mixed evidence on improved downstream clinical outcomes

    inv-07: Gastrointestinal: medically necessary contexts

    Covered when ALL of the following are met for gastrointestinal multiplex testing

    GI panel coverage: Patient presents with moderate to severe diarrhea (eg bloody, febrile, dysenteric, persistent >7 days) OR is hospitalized, a nosocomial case, or is immunocompromised; AND testing is expected to influence clinical management.

    IDSA 2024 guidance supports testing in these contexts; avoid testing for self-limited non-inflammatory diarrhea

    inv-08: C. difficile: testing algorithm and indications

    Covered when ALL of the following are met for C. difficile testing

    C. difficile testing: Only test stool from patients with diarrhea (>=3 unformed stools in 24 hours); use a multistep algorithm pairing a highly sensitive assay (NAAT or GDH) with a more specific toxin EIA; avoid repeat testing and testing for cure.>=3 unformed stools in 24 hours

    ACG and IDSA/SHEA recommend multistep algorithms and discourage repeat testing

    inv-09: Respiratory: when multiplex testing is appropriate

    Covered when ANY of the following are met for respiratory multiplex testing

    Respiratory panel coverage: Patient is hospitalized with severe community-acquired pneumonia, is critically ill/ICU, or is immunocompromised and results are likely to change therapy; panels that include SARS-CoV-2 are supported for symptomatic or exposed individuals.

    IDSA: optional for mild outpatient CAP; prioritize testing in high-risk patients

    inv-10: Central nervous system: NAAT testing

    Covered when ALL of the following are met for CNS testing

    CNS NAAT coverage: CSF NAAT is appropriate for suspected enteroviral CNS infection or when signs of CNS involvement/acute flaccid myelitis are present; ensure the panel covers necessary targets as some (eg parechovirus) require specific NAATs.

    IDSA recommends CSF NAAT for enteroviral CNS infection and cautions that some targets require specific assays

    inv-11: Genitourinary: multiplex testing in high-risk patients

    Covered when ALL of the following are met for genitourinary/STI panels

    GU/STI panel coverage: Individuals at higher risk for sexually transmitted infections or with clinical indications where multiplex testing detects additional infections (eg Chlamydia trachomatis and Neisseria gonorrhoeae) that will change management.

    IDSA: increases detection in high-risk populations

    inv-12: Laboratory validation and diagnostic stewardship

    Implementation considerations

    Laboratory adoption criteria: Laboratories should validate panels, demonstrate clinical validity and utility in their patient population, and apply diagnostic stewardship before broad adoption.

    Joint AMP/ASM/IDSA/PASCV report 2023 emphasizes diagnostic stewardship and demonstration of clinical utility

    inv-13: Respiratory testing recommendations

    Guidance and specialty recommendations relevant to test ordering

    Respiratory panel ordering guidance: Do not routinely order broad respiratory pathogen panels unless the result will affect patient management (ASCP/ChoosingWisely); for hospitalized patients with acute respiratory illness, CDC recommends multiplex nucleic acid detection assay for influenza A/B/SARS-CoV-2 or, if unavailable, order SARS-CoV-2 and influenza assays separately.

    ASCP and CDC guidance quoted in policy; order panels only when results will change management

    inv-14: Solid organ transplant — GI multiplex panels

    Transplant patient guidance

    Transplant GI infection testing: For solid organ transplant recipients with suspected gastrointestinal infections, gastrointestinal multiplex molecular assays are recommended to identify Cryptosporidium, Cyclospora, and Giardia.

    American Society of Transplantation Infectious Diseases COP recommendation

    inv-15: C. difficile interpretation caution

    C. difficile and multiplex testing caution

    C. difficile testing caution: FDA-approved PCR assays for C. difficile are highly sensitive and specific but may be positive in asymptomatic individuals; multiplex molecular results should be interpreted with caution due to lower pre-test probability and risk of over-diagnosis.

    CDC warns that molecular assays can be positive in asymptomatic persons and to read multiplex results with caution

    The policy specifies that molecular detection-based panel testing of urine pathogens for diagnosis of urinary tract infections (e.g., GENETWORx Molecular PCR UTI Test) DOES NOT MEET CRITERIA for outpatient coverage. This exclusion applies to molecular or multiplex urine panels intended to diagnose UTI because available literature does not demonstrate required clinical benefit in the outpatient setting.

    The policy discourages routine use of broad, expanded multiplex respiratory panels in immunocompetent outpatients with mild or moderate illness because results for non-influenza pathogens rarely change management. It favors targeted, point-of-care testing for high-impact pathogens (for example, influenza A/B, RSV, SARS‑CoV‑2) and allows expanded panels primarily when they will alter clinical decisions or in higher-risk populations.

    Routine multiplex panel testing is not recommended for self-limited, non-inflammatory outpatient infections (for example, uncomplicated acute cough or uncomplicated UTIs) where diagnostic testing is unlikely to change treatment. Professional guidance advises withholding broad microbiologic testing unless results would influence therapeutic approach.

    The European Association of Urology guidelines for uncomplicated and complicated urinary tract infections recommend bacterial culture or dipstick testing and do not reference routine molecular multiplex testing in the diagnostic algorithm, implying molecular panels are not endorsed for routine UTI diagnosis.

    In the policy's evidence references section there are no explicit exclusions listed beyond the guidance already stated in the coverage and exclusions sections.

    The policy considers broad multiplex testing (for example, large gastrointestinal or respiratory panels) not medically necessary in many outpatient contexts due to limited evidence of clinical benefit, potential to detect colonization or prolonged shedding, and minimal impact on management for immunocompetent patients. For GI panels, the policy limits outpatient coverage to panels of up to 11 targets no more often than once every 7 days; larger GI panels (≥12 targets) do not meet criteria.

    Expanded multiplex respiratory panels as first-line testing in low-risk, immunocompetent outpatients with mild respiratory illness are generally discouraged because detection of non-influenza targets rarely affects clinical decision-making. The policy recommends preferring targeted testing for influenza/RSV/SARS‑CoV‑2 and reserving broader NAAT panels for immunocompromised, critically ill, or otherwise high-impact situations.

    Use of multiplex panels to detect Clostridioides difficile or other pathogens in settings with low pre-test probability (asymptomatic individuals, routine screening, or when a positive NAAT likely represents colonization) is discouraged. For C. difficile the CDC cautions that molecular assays can be positive in asymptomatic individuals and multiplex results should be interpreted with caution.

    Professional societies (ASCP/ChoosingWisely, CDC) recommend against routine ordering of broad respiratory pathogen panels when results will not affect patient management. Such routine orders in low‑risk outpatient settings are discouraged because they may not change therapy and can contribute to over-testing and excess cost.

    Within the evidence references section itself, the policy notes that there are no additional explicit 'not medically necessary' statements beyond those detailed in the coverage and not medically necessary sections.

    Procedure and Proprietary Codes

    Mentioned commercial multiplex panelsmixed
    BioFire FilmArray RP2.1FDA-approved respiratory panel detecting 18 viral and 4 bacterial pathogens (includes SARS-CoV-2)
    GenMark ePlex Respiratory Pathogen Panel / RP2FDA-approved respiratory pathogen panels (viral and bacterial targets)
    BioFire FilmArray Meningitis/Encephalitis panelFDA-approved panel detecting 14 CNS pathogens from CSF
    T2Bacteria PanelFDA-cleared direct-from-blood sepsis bacterial panel detecting common sepsis pathogens including ESKAPE
    Cobas ePlex BCID panels (GP, GN, FP)FDA-cleared blood culture identification panels for gram-positive, gram-negative, and fungal targets plus resistance genes
    BioFire FilmArray BCID/BCID2Blood culture identification panels (expanded to 43 targets in BCID2)
    MicroGenDX UroKEYNGS-based UTI panel claiming detection of >57,000 bacteria and fungi
    Pathnostics Guidance® UTIPCR + pooled antibiotic susceptibility test identifying 27 organisms and 32 resistance genes
    Procedure and Proprietary Codes (examples listed)CPT | HCPCS | mixed
    0142UInfectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including SARS-CoV-2, qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected
    0202UInfectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including SARS-CoV-2, qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected
    0115URespiratory infectious agent detection by nucleic acid (DNA and RNA), 18 viral types and subtypes and 2 bacterial targets, amplified probe technique, each analyte reported as detected or not detected (ePlex Respiratory Pathogen Panel)
    0068UCandida species panel, amplified probe technique, qualitative report of presence/absence of each species (MycoDART-PCR)
    0442UInfectious disease (bacteria, viruses, fungi, and parasites), cerebrospinal fluid (CSF), metagenomic next-generation sequencing (DNA and RNA), bioinformatic analysis, with positive pathogen identification (MSCSF)
    0441UInfectious disease (bacterial, fungal, or viral infection), semiquantitative biomechanical assessment (via deformability cytometry), whole blood, with algorithmic analysis
    0564UBioFire® SPOTFIRE® Respiratory/Sore Throat (R/ST) Panel - Respiratory/Sore Throat menu (upper respiratory specimen) each pathogen reported as positive or negative
    0590UInfectious disease (bacterial and fungal), DNA of 44 organisms (34 bacteria, 10 fungi), urine, next-generation sequencing, reported as positive or negative for each organism (BIOTIA-ID Urine NGS Assay)
    0593UInfectious disease (genitourinary pathogens), DNA, 46 targets (28 pathogens, 18 resistance genes), RT-PCR amplified probe technique, urine, each analyte reported as detected or not detected
    General CPT/HCPCS panel descriptorsCPT | HCPCS
    unspecified CPT descriptorsInfectious agent detection by nucleic acid (DNA or RNA); panels described by target ranges (3-5, 6-11, 12-25 targets) for gastrointestinal and respiratory pathogens; antigen detection codes for combined SARS-CoV-2 and influenza A/B and/or RSV
    Gastrointestinal panel frequency
    ThresholdGastrointestinal multiplex PCR panel testing (up to 11 GIPs) may be performed no more often than once every 7 days in the outpatient setting.
    SettingOutpatient only — criteria do not apply to non-outpatient settings.
    IndicationPersistent diarrhea or diarrhea with signs/risk factors for severe disease (fever, bloody diarrhea, dysentery, dehydration, severe abdominal pain).
    LimitMultiplex PCR-based panel testing of 12 or more GIPs DOES NOT MEET CRITERIA.
    C. difficile testing symptom threshold
    Symptom threshold

    Provider Actions, Prior Authorization & Documentation

    Prior Authorization

    Outpatient testing authorization note

    This policy applies to outpatient testing and specifies which multiplex panels meet or do not meet coverage criteria; authorization may be required per the member's benefit and the policy guidance should be used when requesting coverage.

    Prior Authorization

    Respiratory panel prior authorization guidance

    Prior authorization is appropriate for broad, expanded multiplex respiratory panels when clinical documentation does not demonstrate a high pre-test probability or when multiple low-impact targets unlikely to change management are requested; targeted tests for high-impact pathogens (influenza A/B, RSV, SARS‑CoV‑2) are preferred.

    Prior Authorization

    Prior authorization for low-risk outpatient panel orders

    Prior authorization is required when multiplex panels are ordered for low-risk outpatients or routine screening without documented high-risk features; panels intended primarily for hospitalized, immunocompromised, or critically ill patients are more likely to be authorized.

    Background and Policy Scope

    Multiplex PCR and antigen panels permit detection of multiple pathogens from a single specimen and are generally more sensitive and faster than many conventional methods. Antigen panels are less sensitive but useful for rapid, point‑of‑care testing; expanded molecular panels have higher diagnostic yield but can detect colonization or prolonged shedding, which may limit clinical utility in many outpatient populations.

    Definitions and Abbreviations

    inv-60: GIPs — Gastrointestinal pathogens (abbreviation used for panels targeting bacterial, viral, and parasitic GI agents).
    DefinitionGIPs = Gastrointestinal pathogens; abbreviation used for panels targeting bacterial, viral, and parasitic GI agents
    Use caseGIP panels applied to evaluate etiology of diarrheal disease and outbreak investigation contexts
    Panel target rangesPolicy examples reference GI panels with target ranges from 3–25, with up to 11 targets meeting outpatient criteria
    inv-61: NAAT / PCR — Nucleic acid amplification test / polymerase chain reaction — molecular methods used for pathogen detection.
    DefinitionNAAT/PCR = Nucleic acid amplification test / polymerase chain reaction — molecular methods used for pathogen detection
    Performance

    Revision History & References

    No explicit exclusions are listed in the evidence references portion of the policy beyond the specific exclusions and not‑medically‑necessary determinations already described elsewhere in the document.

    Policy Summary
    PayerOscar Health
    PolicyPathogen Panel Testing
    Policy CodePolicy N/A
    Change TypeRoutine review — no material changes
    Effective DateOct 1, 2026
    Last ReviewJun 16, 2026
    Next Review DateJun 16, 2026
    Key ActionObtain prior authorization when broad multiplex panels are ordered for low‑risk outpatients or when member benefits require authorization; document clinical justification.
    SourceLink
    On This Page
    Coverage Criteria for Multiplex Pathogen PanelsProcedure and Proprietary CodesProvider Actions, Prior Authorization & DocumentationBackground and Policy ScopeDefinitions and AbbreviationsRevision History & References

    Not covered in outpatient setting per this policy portion; see CNS criteria for exceptions when CSF findings support testing

    Blood-based molecular panels: Molecular detection-based panel testing of pathogens in the blood DOES NOT MEET CRITERIA.blood panels

    Not covered for outpatient use per policy portion

    Urine and wound molecular panels: Molecular detection-based panel testing of urine pathogens for diagnosis of UTI and molecular-based panel testing to screen for or diagnose wound infections DOES NOT MEET CRITERIA.urine/wound panels

    Examples cited include GENETWORx molecular UTI and wound tests

    Test stool for C. difficile only in patients with diarrhea defined as 3 or more unformed stools in 24 hours.
    Testing algorithmUse a multistep algorithm pairing a highly sensitive assay (NAAT or GDH) with a more specific toxin EIA to distinguish colonization from active infection.
    Repeat testingRepeat testing should be discouraged; testing for cure should not be performed.
    Evidence sourceACG recommendations (2013; reaffirmed 2021) supporting symptom threshold and multistep testing approach.
    C. difficile stool frequency threshold
    Stool frequencyC. difficile testing should be limited to patients with ≥3 unformed stools within a 24-hour period.
    RationaleOnly individuals with symptoms suggestive of active CDI should be tested to reduce detection of colonization.
    Recommended pairingPair NAAT/GDH with a toxin EIA as part of a two-step algorithm for diagnostic accuracy.
    Billing Rule

    Use listed procedure codes for authorization

    Use the specific CPT/HCPCS and proprietary laboratory test codes listed in the policy (including multiple proprietary U-codes and panel descriptors) when requesting authorization or submitting claims; reference the exact code corresponding to the panel performed.

    Prior Authorization

    Prior authorization

    No prior authorization requirements are specified in the evidence references and publication history section of this policy.

    Step Therapy

    Step therapy

    No step therapy requirements are specified in this portion of the policy.

    Step Therapy

    Prefer targeted respiratory testing first

    Favor targeted point-of-care testing for influenza, RSV, and SARS‑CoV‑2 before ordering larger multiplex respiratory panels in immunocompetent outpatients with mild to moderate illness, because point-of-care influenza testing has greater demonstrated impact on clinical outcomes.

    Step Therapy

    C. difficile multistep testing

    For suspected C. difficile infection, perform testing only for patients with diarrhea (≥3 unformed stools in 24 hours) and follow a multistep algorithm pairing a highly sensitive assay (NAAT or GDH) with a more specific toxin EIA rather than NAAT alone.

    • Test stool only from patients with ≥3 unformed stools in 24 hours.
    • Use NAAT or GDH first paired with toxin EIA as the second step.
    Step Therapy

    Conservative testing preferred

    Do not routinely order broad respiratory pathogen panels unless the result will affect patient management; conservative use is recommended by ASCP/ChoosingWisely.

    Step Therapy

    Step therapy (none specified)

    No step therapy requirements are specified in this section of the policy.

    Documentation Required

    Documentation and coding

    Providers must submit accurate documentation of services performed and code claims according to industry standard coding guidelines; failure to follow appropriate coding/billing guidelines or current reimbursement policies may result in denial or recoupment.

    • Document services and select codes per CPT/HCPCS and industry standards.
    • Claims may be denied or recouped if documentation or coding is inaccurate.
    Documentation Required

    CSF pre-test screening documentation

    Before ordering molecular CSF testing, document CSF cell count, glucose, and protein analyses as screening; elevated leukocyte count or protein or heightened clinical suspicion (e.g., suspected HSV encephalitis) should be recorded to support molecular testing.

    Documentation Required

    Blood culture adjunct documentation

    When multiplex PCR is used as an adjunct after a positive blood culture, document the positive culture and clinical rationale (for example, prior antibiotic exposure or need for rapid identification) to justify molecular testing.

    Documentation Required

    C. difficile test documentation

    For C. difficile testing, document the presence of diarrhea (≥3 unformed stools in 24 hours) and that testing follows a multistep algorithm (NAAT/GDH plus toxin EIA); avoid repeat testing and record clinical signs consistent with active CDI.

    • Document ≥3 unformed stools in 24 hours.
    • Document use of a multistep testing algorithm (NAAT/GDH + toxin EIA).
    • Avoid and document that repeat testing is not performed.
    Documentation Required

    Document clinical justification for multiplex panels

    Document clinical justification and relevant risk factors when ordering multiplex panels (for example: hospitalization, immunocompromise, persistent or severe symptoms, travel/exposure for parasites, or outbreak settings) to support medical necessity.

    Billing Rule

    Procedure coding documentation

    Document the specific test performed using the CPT/HCPCS and proprietary codes listed in the policy (including proprietary U-codes and panel descriptors) to support billing and coverage determinations.

    Note

    Evidence/publication documentation note

    This evidence references section and the publication history do not specify additional provider documentation or submission requirements.

    Denial Risk

    Coding and documentation risk

    Claims may be denied or recouped if coding/billing guidelines or current reimbursement policies are not followed and if documentation is inaccurate.

    Denial Risk

    Non‑covered panel triggers

    Tests designated as DOES NOT MEET CRITERIA in the policy—such as multiplex gastrointestinal panels with 12 or more targets and molecular panels for CSF, blood, urine, or wound—are at risk for denial.

    Denial Risk

    CSF testing precondition

    Ordering multiplex PCR CSF tests without correlating CSF findings (for example, elevated leukocyte count or protein) increases false positives and reduces predictive value; tests should be ordered only when moderate-to-high pre-test probability exists and supporting CSF results are documented.

    Denial Risk

    Respiratory panel actionability

    Broad multiplex respiratory panels in immunocompetent patients with mild or moderate illness often do not change management; use of targeted testing is favored and ordering broad panels without justification risks denial.

    Denial Risk

    GI testing limited to specific clinical contexts

    Gastrointestinal panel testing may be denied if performed outside the specified clinical contexts (non-inflammatory, self-limited diarrhea or short-duration gastroenteritis); reserve testing for moderate-severe, bloody/febrile/dysenteric illness, >7 days duration, nosocomial cases, or immunocompromised individuals.

    Denial Risk

    Respiratory panel use limited to higher-acuity patients

    Respiratory multiplex panels are expected to be targeted to hospitalized, immunocompromised, or severely ill patients; routine outpatient testing in mild CAP or low-risk outpatients may be denied.

    Denial Risk

    Conflict with government policy

    If there is a conflict between this policy and an applicable government policy (for example, Medicare LCDs/NCDs or state Medicaid rules), the government policy will govern coverage determinations; failure to follow applicable government policies could trigger denial.

    Denial Risk

    Denial triggers (none in references)

    No denial triggers are listed in the evidence references section of the policy.

    Multiplex NAATs are highly sensitive and are the current gold standard for viral respiratory diagnosis
    Specimen typesUsed across respiratory, GI, CSF, blood, urine and other specimen types as described in policy
    inv-62: Multiplex NAAT/PCR — Nucleic acid amplification tests that detect multiple viral and bacterial targets simultaneously; gold standard for viral respiratory dia...
    DefinitionMultiplex NAAT/PCR = nucleic acid amplification tests that detect multiple viral and bacterial targets simultaneously
    Clinical roleConsidered gold standard for viral respiratory diagnosis with rapid, sensitive and specific results
    Target range examplesPolicy cites multiplex respiratory panels ranging from small (3–5 targets) to expanded panels (up to 25 targets or more)
    inv-63: FilmArray Meningitis/Encephalitis panel — An FDA-approved multiplex PCR assay that detects 14 CNS pathogens from 0.2 mL CSF with reported sensitivity ~94.2% and specificity ~99.8%.
    Device exampleFilmArray Meningitis/Encephalitis panel — FDA-approved multiplex PCR that detects 14 CNS pathogens from 0.2 mL CSF
    Reported performanceReported overall sensitivity ~94.2% and specificity ~99.8% per manufacturer data cited
    TurnaroundProvides results in approximately one hour using small CSF volume (0.2 mL)
    inv-64: Multistep algorithm for C. difficile — A testing approach that pairs a highly sensitive assay (NAAT or GDH) with a more specific toxin EIA (eg, GDH plus toxin, or NAAT plus tox...
    ApproachMultistep algorithm for C. difficile pairs a highly sensitive assay (NAAT or GDH) with a more specific toxin EIA (eg, GDH plus toxin, or NAAT plus toxin)
    RationaleThis strategy helps distinguish colonization from active infection and is preferred over NAAT alone
    Guideline supportRecommended by ACG and IDSA/SHEA guidance cited in the policy
    inv-65: Diagnostic stewardship — Deliberate selection of tests and patient populations for multiplex panels to maximize clinical utility and limit unnecessary testing and...
    PrincipleDiagnostic stewardship = deliberate selection of tests and patient populations for multiplex panels to maximize clinical utility and limit unnecessary testing
    Recommended applicationLimit broad multiplex panel use to hospitalized, immunocompromised, or high-acuity patients; favor targeted testing in low-risk outpatients
    ImplementationLaboratories should validate panels and demonstrate clinical utility before broad adoption
    inv-66: Laboratory-developed test (LDT) — A test developed and validated by a laboratory and regulated as a high-complexity test under CLIA '88; not FDA-cleared or -approved but a...
    DefinitionLaboratory-developed test (LDT) = a test developed and validated by a laboratory and regulated as a high-complexity test under CLIA '88; not FDA-cleared or -approved
    Regulatory noteLDTs are permitted for clinical use but are not FDA-approved or cleared; labs must validate performance
    ContextMany laboratories develop in-house assays alongside FDA-approved commercial panels
    inv-67: Multiplex nucleic acid detection assay / panel — A molecular assay that detects multiple pathogen targets (ranges in policy examples include 3–5, 6–11, 12–25 targets and proprietary pane...
    DefinitionMultiplex nucleic acid detection assay/panel = molecular assay detecting multiple pathogen targets; policy examples include ranges of 3–5, 6–11, 12–25 targets and proprietary panels
    ExamplesUsed across specimen types (respiratory, GI, CSF, blood) with commercial platforms cited such as BioFire, ePlex, QIAstat-Dx
    ImplicationPanel size affects coverage stance: smaller panels often meet criteria in outpatients while larger panels may not
    inv-68: Multiplex pathogen panels — Commercial assays and panels (respiratory, ME, BCID, GI, urinary, wound) that detect multiple pathogens simultaneously using molecular me...
    ScopeMultiplex pathogen panels = commercial assays (respiratory, ME, BCID, GI, urinary, wound) that detect multiple pathogens simultaneously using molecular methods
    Platform examplesExamples cited include FilmArray, ePlex, T2Bacteria, cobas ePlex, BioFire BCID/BCID2
    Clinical considerationsThese panels increase diagnostic yield but may detect colonization or prolonged shedding, requiring cautious interpretation